메뉴 건너뛰기




Volumn 28, Issue 4, 2011, Pages 270-278

Fingolimod: An oral disease-modifying therapy for relapsing multiple sclerosis

Author keywords

Fingolimod; Multiple sclerosis; Sphingosine 1 phosphate receptor modulator

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; G PROTEIN COUPLED RECEPTOR; PLACEBO; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

EID: 79958205590     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0004-6     Document Type: Review
Times cited : (22)

References (38)
  • 1
    • 77950610036 scopus 로고    scopus 로고
    • The changing demographic pattern of multiple sclerosis epidemiology
    • Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010;9:520-532.
    • (2010) Lancet Neurol , vol.9 , pp. 520-532
    • Koch-Henriksen, N.1    Sorensen, P.S.2
  • 2
    • 0029913882 scopus 로고    scopus 로고
    • Defining the clinical course of multiple sclerosis: Results of an international survey
    • National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.
    • Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46:907-911.
    • (1996) Neurology , vol.46 , pp. 907-911
    • Lublin, F.D.1    Reingold, S.C.2
  • 6
    • 49449086845 scopus 로고    scopus 로고
    • Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis
    • Krishnan C, Kaplin AI, Brodsky RA, et al. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol. 2008;65:1044-1051.
    • (2008) Arch Neurol , vol.65 , pp. 1044-1051
    • Krishnan, C.1    Kaplin, A.I.2    Brodsky, R.A.3
  • 7
    • 33745938938 scopus 로고    scopus 로고
    • Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis-reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations
    • Then Bergh F, Kumpfel T, Schumann E, et al. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis-reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol. 2006;6:19.
    • (2006) BMC Neurol , vol.6 , pp. 19
    • Then Bergh, F.1    Kumpfel, T.2    Schumann, E.3
  • 8
    • 0031057970 scopus 로고    scopus 로고
    • Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis
    • Austrian Immunoglobulin in Multiple Sclerosis Study Group
    • Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet. 1997;349:589-593.
    • (1997) Lancet , vol.349 , pp. 589-593
    • Fazekas, F.1    Deisenhammer, F.2    Strasser-Fuchs, S.3    Nahler, G.4    Mamoli, B.5
  • 9
    • 76149083915 scopus 로고    scopus 로고
    • A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis
    • Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416-426.
    • (2010) N Engl J Med , vol.362 , pp. 416-426
    • Giovannoni, G.1    Comi, G.2    Cook, S.3
  • 10
    • 76149093586 scopus 로고    scopus 로고
    • A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis
    • Kappos L, Radue EW, O'Connor P, et al. A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387-401.
    • (2010) N Engl J Med , vol.362 , pp. 387-401
    • Kappos, L.1    Radue, E.W.2    O'Connor, P.3
  • 11
    • 77951073508 scopus 로고    scopus 로고
    • Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis
    • Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33:91-101.
    • (2010) Clin Neuropharmacol , vol.33 , pp. 91-101
    • Chun, J.1    Hartung, H.P.2
  • 12
    • 40649122843 scopus 로고    scopus 로고
    • FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology
    • Adachi K, Chiba K. FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology. Perspect Medicin Chem. 2008;1:11-23.
    • (2008) Perspect Medicin Chem , vol.1 , pp. 11-23
    • Adachi, K.1    Chiba, K.2
  • 13
  • 14
    • 0028372227 scopus 로고
    • Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite
    • Fujita T, Inoue K, Yamamoto S, et al. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot. 1994;47:208-215.
    • (1994) J Antibiot , vol.47 , pp. 208-215
    • Fujita, T.1    Inoue, K.2    Yamamoto, S.3
  • 15
    • 0037162038 scopus 로고    scopus 로고
    • Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: Is this an atherogenic mediator or an anti-atherogenic mediator?
    • Okajima F. Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator? Biochim Biophys Acta. 2002;1582:132-137.
    • (2002) Biochim Biophys Acta , vol.1582 , pp. 132-137
    • Okajima, F.1
  • 16
    • 0242411518 scopus 로고    scopus 로고
    • 1 acts within endothelial cells to regulate vascular maturation
    • DOI 10.1182/blood-2003-02-0460
    • Allende ML, Yamashita T, Proia RL. G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood. 2003;102:3665-3667. (Pubitemid 37409386)
    • (2003) Blood , vol.102 , Issue.10 , pp. 3665-3667
    • Allende, M.L.1    Yamashita, T.2    Proia, R.L.3
  • 18
    • 46949104885 scopus 로고    scopus 로고
    • "Insideout" signaling of sphingosine-1-phosphate: Therapeutic targets
    • Takabe K, Paugh SW, Milstien S, Spiegel S. "Insideout" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev. 2008;60:181-195.
    • (2008) Pharmacol Rev , vol.60 , pp. 181-195
    • Takabe, K.1    Paugh, S.W.2    Milstien, S.3    Spiegel, S.4
  • 19
    • 34250832664 scopus 로고    scopus 로고
    • Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology
    • DOI 10.1016/j.pharmthera.2007.04.006, PII S0163725807000836
    • Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007;115:84-105. (Pubitemid 46990553)
    • (2007) Pharmacology and Therapeutics , vol.115 , Issue.1 , pp. 84-105
    • Brinkmann, V.1
  • 20
    • 0037162095 scopus 로고    scopus 로고
    • Pathways of transduction engaged by sphingosine 1-phosphate through G protein-coupled receptors
    • DOI 10.1016/S1388-1981(02)00142-7, PII S1388198102001427
    • Siehler S, Manning DR. Pathways of transduction engaged by sphingosine 1-phosphate through G protein-coupled receptors. Biochim Biophys Acta. 2002;1582:94-99. (Pubitemid 34634116)
    • (2002) Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids , vol.1582 , Issue.1-3 , pp. 94-99
    • Siehler, S.1    Manning, D.R.2
  • 24
    • 77955358808 scopus 로고    scopus 로고
    • Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis
    • Mehling M, Lindberg R, Raulf F, et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology. 2010;75:403-410.
    • (2010) Neurology , vol.75 , pp. 403-410
    • Mehling, M.1    Lindberg, R.2    Raulf, F.3
  • 26
    • 69949124388 scopus 로고    scopus 로고
    • Fingolimod and related compounds in a spontaneous autoimmune polyneuropathy
    • Kim HJ, Jung CG, Dukala D, et al. Fingolimod and related compounds in a spontaneous autoimmune polyneuropathy. J Neuroimmunol. 2009;214:93-100.
    • (2009) J Neuroimmunol , vol.214 , pp. 93-100
    • Kim, H.J.1    Jung, C.G.2    Dukala, D.3
  • 27
    • 66849115613 scopus 로고    scopus 로고
    • Immunomodulatory drug FTY720 induces regulatory CD4(+)CD25(+) T cells in vitro
    • Zhou PJ, Wang H, Shi GH, Wang XH, Shen ZJ, Xu D. Immunomodulatory drug FTY720 induces regulatory CD4(+)CD25(+) T cells in vitro. Clin Exp Immunol. 2009;157:40-47.
    • (2009) Clin Exp Immunol , vol.157 , pp. 40-47
    • Zhou, P.J.1    Wang, H.2    Shi, G.H.3    Wang, X.H.4    Shen, Z.J.5    Xu, D.6
  • 28
    • 70349333237 scopus 로고    scopus 로고
    • The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo
    • Wolf AM, Eller K, Zeiser R, et al. The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo. J Immunol. 2009;183:3751-3760.
    • (2009) J Immunol , vol.183 , pp. 3751-3760
    • Wolf, A.M.1    Eller, K.2    Zeiser, R.3
  • 29
    • 70849086174 scopus 로고    scopus 로고
    • FTY720 (fingolimod) in multiple sclerosis: Therapeutic effects in the immune and the central nervous system
    • Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol. 2009;158:1173-1182.
    • (2009) Br J Pharmacol , vol.158 , pp. 1173-1182
    • Brinkmann, V.1
  • 31
    • 77956568581 scopus 로고    scopus 로고
    • Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions
    • Van Doorn R, Van Horssen J, Verzijl D, et al. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glia. 2010;58:1465-1476.
    • (2010) Glia , vol.58 , pp. 1465-1476
    • Van Doorn, R.1    Van Horssen, J.2    Verzijl, D.3
  • 32
    • 0030049234 scopus 로고    scopus 로고
    • A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation
    • DOI 10.1097/00007890-199601270-00006
    • Suzuki S, Enosawa S, Kakefuda T, et al. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation. 1996;61:200-205. (Pubitemid 26046580)
    • (1996) Transplantation , vol.61 , Issue.2 , pp. 200-205
    • Suzuki, S.1    Enosawa, S.2    Kakefuda, T.3    Shinomiya, T.4    Amari, M.5    Naoe, S.6    Hoshino, Y.7    Chiba, K.8
  • 33
    • 0029996293 scopus 로고    scopus 로고
    • FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats
    • Chiba K, Hoshino Y, Suzuki C, et al. FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats. Transplant Proc. 1996;28:1056-1059.
    • (1996) Transplant Proc , vol.28 , pp. 1056-1059
    • Chiba, K.1    Hoshino, Y.2    Suzuki, C.3
  • 35
    • 63849147004 scopus 로고    scopus 로고
    • Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study
    • O'Connor P, Comi G, Montalban X, et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology. 2009;72:73-79.
    • (2009) Neurology , vol.72 , pp. 73-79
    • O'Connor, P.1    Comi, G.2    Montalban, X.3
  • 36
    • 76449120437 scopus 로고    scopus 로고
    • Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results
    • Comi G, O'Connor P, Montalban X, et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler. 2010;16:197-207.
    • (2010) Mult Scler , vol.16 , pp. 197-207
    • Comi, G.1    O'Connor, P.2    Montalban, X.3
  • 37
    • 76149140914 scopus 로고    scopus 로고
    • Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
    • Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402-415.
    • (2010) N Engl J Med , vol.362 , pp. 402-415
    • Cohen, J.A.1    Barkhof, F.2    Comi, G.3
  • 38
    • 79551495392 scopus 로고    scopus 로고
    • Fingolimod provides long-term protection in rodent models of cerebral ischemia
    • Wei Y, Yemisci M, Kim HH, et al. Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol. 2011;69:119-129.
    • (2011) Ann Neurol , vol.69 , pp. 119-129
    • Wei, Y.1    Yemisci, M.2    Kim, H.H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.